2026-06-30 0001912966 false --12-31 Q2 0001912966 2026-01-01 2026-06-30 0001912966 2025-01-01 2025-06-30 0001912966 srt:MinimumMember rgnt:GlobalSalesMember 2026-01-01 2026-06-30 0001912966 srt:MaximumMember rgnt:GlobalSalesMember 2026-01-01 2026-06-30 0001912966 rgnt:CSLMember 2026-01-01 2026-06-30 0001912966 2025-07-04 2025-07-04 0001912966 rgnt:CSLMember 2025-07-04 2025-07-04 0001912966 rgnt:CSLMember 2020-01-14 2020-01-14 0001912966 2026-06-30 0001912966 2026-01-01 2026-01-31 0001912966 2026-01-31 0001912966 2008-07-01 2008-07-31 0001912966 rgnt:BaxterServicesMember 2018-02-01 2018-02-28 0001912966 rgnt:BaxterServicesMember rgnt:ServicesAgreementMember 2018-02-01 2018-02-28 0001912966 srt:MaximumMember 2026-01-01 2026-06-30 0001912966 srt:MinimumMember 2026-01-01 2026-06-30 0001912966 rgnt:FinanceExpenseNetMember 2026-01-01 2026-06-30 0001912966 rgnt:GeneralAndAdministrativeExpensesMember 2026-01-01 2026-06-30 0001912966 rgnt:ResearchAndDevelopmentExpensesMember 2026-01-01 2026-06-30 0001912966 srt:DirectorMember 2026-06-04 0001912966 srt:DirectorMember 2026-06-04 2026-06-04 0001912966 us-gaap:StockOptionMember 2026-05-28 0001912966 us-gaap:StockOptionMember 2026-05-28 2026-05-28 0001912966 rgnt:FormerLendersMember 2026-02-23 0001912966 rgnt:FormerLendersMember 2026-07-09 0001912966 rgnt:FormerLendersMember 2026-02-23 2026-02-23 0001912966 srt:DirectorMember 2026-02-23 0001912966 srt:DirectorMember 2026-07-09 0001912966 srt:DirectorMember 2026-02-23 2026-02-23 0001912966 us-gaap:StockOptionMember 2026-02-23 0001912966 us-gaap:StockOptionMember 2026-02-23 2026-02-23 0001912966 us-gaap:WarrantMember 2026-06-30 0001912966 us-gaap:WarrantMember 2026-01-01 2026-06-30 0001912966 us-gaap:PrivatePlacementMember 2026-01-01 2026-06-30 0001912966 us-gaap:PrivatePlacementMember 2026-06-30 0001912966 2025-12-31 0001912966 rgnt:AprilTwentyTwentyFourLoanMember 2026-06-30 0001912966 rgnt:DecemberTwentyTwentyFourLoanMember 2026-06-30 0001912966 us-gaap:BridgeLoanMember 2026-06-30 0001912966 rgnt:JanuaryTwentyTwentyFourLoanMember 2026-06-30 0001912966 us-gaap:WarrantMember 2025-12-31 0001912966 us-gaap:IPOMember us-gaap:WarrantMember 2026-06-30 0001912966 rgnt:AprilTwentyTwentyFourLoanMember 2025-01-01 2025-12-31 0001912966 rgnt:AprilTwentyTwentyFourLoanMember 2025-12-31 0001912966 rgnt:DecemberTwentyTwentyFourLoanMember 2025-01-01 2025-12-31 0001912966 rgnt:DecemberTwentyTwentyFourLoanMember 2025-12-31 0001912966 rgnt:OctoberNovember2024BridgeLoansMember 2025-01-01 2025-12-31 0001912966 rgnt:OctoberNovember2024BridgeLoansMember 2025-12-31 0001912966 rgnt:JanuaryTwentyTwentyFourLoanMember 2025-01-01 2025-12-31 0001912966 rgnt:JanuaryTwentyTwentyFourLoanMember 2025-12-31 0001912966 2023-08-31 0001912966 rgnt:WarrantsWithAnExercisePriceOfDollarFourPointThreeSevenFiveMember 2026-01-01 2026-06-30 0001912966 rgnt:WarrantsWithAnExercisePriceOfDollarFourPointTwoZeroMember 2026-01-01 2026-06-30 0001912966 rgnt:WarrantsWithAnExercisePriceOf50Member 2026-01-01 2026-06-30 0001912966 rgnt:WarrantsWithAnExercisePriceOf100Member 2026-01-01 2026-06-30 0001912966 rgnt:OptionsWithAnExercisePriceOfDollarFourPointZeroMember 2026-01-01 2026-06-30 0001912966 rgnt:OptionsWithAnExercisePriceOfDollarOnePointFourSixMember 2025-01-01 2025-06-30 0001912966 rgnt:OptionsWithAnExercisePriceOfDollarOnePointFourSixMember 2026-01-01 2026-06-30 0001912966 us-gaap:PreferredStockMember 2025-01-01 2025-06-30 0001912966 us-gaap:CommonStockMember 2025-01-01 2025-06-30 0001912966 us-gaap:CommonStockMember 2026-01-01 2026-06-30 0001912966 2025-06-30 0001912966 us-gaap:ComputerEquipmentMember 2026-06-30 0001912966 us-gaap:ComputerEquipmentMember srt:MaximumMember 2026-06-30 0001912966 us-gaap:ComputerEquipmentMember srt:MinimumMember 2026-06-30 0001912966 us-gaap:EquipmentMember srt:MaximumMember 2026-06-30 0001912966 us-gaap:EquipmentMember srt:MinimumMember 2026-06-30 0001912966 us-gaap:CommonStockMember us-gaap:IPOMember 2025-12-05 2025-12-05 0001912966 us-gaap:IPOMember 2025-12-05 2025-12-05 0001912966 us-gaap:IPOMember 2025-12-05 0001912966 2024-12-31 0001912966 us-gaap:RetainedEarningsMember 2025-06-30 0001912966 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001912966 us-gaap:CommonStockMember 2025-06-30 0001912966 rgnt:ConvertiblePreferredSharesMember 2025-06-30 0001912966 us-gaap:RetainedEarningsMember 2025-01-01 2025-06-30 0001912966 us-gaap:RetainedEarningsMember 2024-12-31 0001912966 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001912966 us-gaap:CommonStockMember 2024-12-31 0001912966 rgnt:ConvertiblePreferredSharesMember 2024-12-31 0001912966 us-gaap:RetainedEarningsMember 2026-06-30 0001912966 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001912966 us-gaap:CommonStockMember 2026-06-30 0001912966 us-gaap:RetainedEarningsMember 2026-01-01 2026-06-30 0001912966 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-06-30 0001912966 us-gaap:RetainedEarningsMember 2025-12-31 0001912966 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001912966 us-gaap:CommonStockMember 2025-12-31 0001912966 rgnt:ConvertiblePreferredSharesMember 2025-01-01 2025-06-30 0001912966 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-06-30 0001912966 us-gaap:PreferredStockMember 2026-01-01 2026-06-30 0001912966 rgnt:WarrantsWithAnExercisePriceOf100Member 2025-01-01 2025-06-30 0001912966 rgnt:WarrantsWithAnExercisePriceOf50Member 2025-01-01 2025-06-30 0001912966 rgnt:WarrantsWithAnExercisePriceOfDollarFourPointTwoZeroMember 2025-01-01 2025-06-30 0001912966 rgnt:OptionsWithAnExercisePriceOfDollarFourPointZeroMember 2025-01-01 2025-06-30 0001912966 rgnt:WarrantsWithAnExercisePriceOfDollarFourPointThreeSevenFiveMember 2025-01-01 2025-06-30 0001912966 rgnt:ResearchAndDevelopmentExpensesMember 2025-01-01 2025-06-30 0001912966 rgnt:GeneralAndAdministrativeExpensesMember 2025-01-01 2025-06-30 iso4217:USD xbrli:pure iso4217:USD xbrli:shares xbrli:shares rgnt:Segment

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of September 2026

 

Commission file number: 001-42834

 

REGENTIS BIOMATERIALS LTD.

(Translation of registrant’s name into English)

 

60 Medinat Hayehudim Street, 4676652, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒       Form 40-F

 

 

 

 

 

Explanatory Note

 

Attached are the Company’s press release providing a business update for the first half of 2026, condensed interim unaudited financial statements and a summary of its operating and financial review and prospects, each as of June 30, 2026, furnished herewith as Exhibits 99.1, 99.2 and 99.3, respectively.

 

This Report on Form 6-K (including the six bullet points following “Corporate and Clinical Highlights:” in Exhibit 99.1 and Exhibits 99.2 and 99.3 ) is hereby incorporated by reference into the registrant’s Registration Statement on Form F-1 (File No. 333-297320), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

1

 

 

Exhibit Index

 

Exhibit No.   Description
99.1   Press Release dated September 11, 2026
99.2   Condensed Interim Unaudited Financial Statements as of June 30, 2026
99.3   Operating and Financial Review and Prospects as of June 30, 2026
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Label Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Presentation Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Definition Linkbase Document
104   Cover Page Interactive Data File formatted as Inline XBRL and contained in Exhibit 101

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Regentis Biomaterials Ltd.
     
Date: September 11, 2026 By: /s/ Ori Gon
    Ori Gon
    Chief Financial Officer

 

3

 


ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

PRESS RELEASE DATED SEPTEMBER 11, 2026

CONDENSED INTERIM UNAUDITED FINANCIAL STATEMENTS AS OF JUNE 30, 2026

OPERATING AND FINANCIAL REVIEW AND PROSPECTS AS OF JUNE 30, 2026

XBRL SCHEMA FILE

XBRL CALCULATION FILE

XBRL DEFINITION FILE

XBRL LABEL FILE

XBRL PRESENTATION FILE

IDEA: R1.htm

IDEA: R2.htm

IDEA: R3.htm

IDEA: R4.htm

IDEA: R5.htm

IDEA: R6.htm

IDEA: R7.htm

IDEA: R8.htm

IDEA: R9.htm

IDEA: R10.htm

IDEA: R11.htm

IDEA: R12.htm

IDEA: R13.htm

IDEA: R14.htm

IDEA: R15.htm

IDEA: R16.htm

IDEA: R17.htm

IDEA: R18.htm

IDEA: R19.htm

IDEA: R20.htm

IDEA: R21.htm

IDEA: R22.htm

IDEA: R23.htm

IDEA: R24.htm

IDEA: R25.htm

IDEA: R26.htm

IDEA: R27.htm

IDEA: R28.htm

IDEA: R29.htm

IDEA: R30.htm

IDEA: R31.htm

IDEA: R32.htm

IDEA: R33.htm

IDEA: R34.htm

IDEA: R35.htm

IDEA: R36.htm

IDEA: FilingSummary.xml

IDEA: MetaLinks.json

IDEA: ea0304771-6k_regentis_htm.xml